Email this article 
Post a Comment Synthetic analogs of vitamin D3 in therapy of psoriasis
- Authors: Petrova I.V.1, Radzhabov R.M.2, Abdulov A.R.2, Manatov M.G.2, Glushakov R.I.3, Proshin S.N.2
-
Affiliations:
- City Hospital of Norilsk No 2, Ministry of Healthcare of Russian Federation
- North-Western State Medical University named after I.I. Mechnikov
- St Petersburg State Pediatric Medical University
- Issue: Vol 16, No 4 (2018)
- Pages: 49-54
- Section: Articles
- URL: https://bakhtiniada.ru/RCF/article/view/11088
- DOI: https://doi.org/10.17816/RCF16449-54
- ID: 11088
Cite item
Full Text
Abstract
Psoriasis is one of the most common skin diseases and occurs in 1-2% of the population of developed countries. The problem of pathogenetic treatment of psoriasis remains relevant despite the annual appearance of new drugs. The anti-keratinizing effect is particularly important in the treatment of psoriasis. The effect is based on suppression of the proliferation of epidermal keratinocytes, normalization of the differentiation of the nonkeratinizing epithelium and the decrease in the adhesion of horny cells. The last decade is characterized by a deepening of ideas about the biological properties and mechanism of action of vitamin D3. However the vitamin D3 does itself not have therapeutic activity. In this connection the use of synthetic analogues of vitamin D3 which have therapeutic activity is particular of importance.
The aim. To evaluate the effectiveness of vitamin D3synthetic analogs for the treatment of psoriasis.
Methods. It was retrospective analysis of multicentric studies by a double-blind, randomized method of the effectiveness of vitamin D3 analogs for the treatment of psoriasis in Russia and foreign clinics. The PASI index in assessing the clinical manifestations of psoriasis.
Rеsults and discussion. The study of the clinical efficacy of oral forms of the vitamin indicates a positive therapeutic effect in 70-90% of patients but this requires an average of 2.8 months. Therefore for the treatment of psoriasis more widely used synthetic analogue of vitamin D3 – calcipotriol (MS-903), developed exclusively for topical application. Calcipotriol gives minimal side effects and has an intense antipsoriatic effect. The mechanism of action of calcipotriol is based on interaction with specific receptors on keratinocytes which causes inhibition of proliferation, accelerates the morphological differentiation of psoriatic cells, inhibits the activity of interleukin-1 and reduces interleukin-2 production, i.e. has an effect on the pathogenetic mechanisms of psoriasis.
Conclusion. Vitamin D3 analogues are effective antipsoriatic drugs that can be used both as monotherapy and in the complex treatment of patients with severe psoriasis.
Full Text
##article.viewOnOriginalSite##About the authors
Inna V. Petrova
City Hospital of Norilsk No 2, Ministry of Healthcare of Russian Federation
Author for correspondence.
Email: doctorinna07@mail.ru
Dermatologist, the Head of Division of Dermatology and Venereology
Russian Federation, NorilskRasul M. Radzhabov
North-Western State Medical University named after I.I. Mechnikov
Email: K281ua05rus@mail.ru
6th year Student of Faculty of General Medical
Russian Federation, Saint PetersburgAbdul R. Abdulov
North-Western State Medical University named after I.I. Mechnikov
Email: Abdulov_97@list.ru
6th year Student of Faculty of General Medical
Russian Federation, Saint PetersburgMagomed G. Manatov
North-Western State Medical University named after I.I. Mechnikov
Email: Dr.7gv@yandex.ru
2nd year Clinical Resident of the Deaprtment of Surgery named after Opel
Russian Federation, Saint PetersburgRuslan I. Glushakov
St Petersburg State Pediatric Medical University
Email: glushakovruslan@gmail.com
Associate Professor of the the Department of Pharmacology, Clinical Pharmacology and Pharmacoeconomy
Russian Federation, Saint PetersburgSergey N. Proshin
North-Western State Medical University named after I.I. Mechnikov
Email: psnjsn@rambler.ru
Head of the Department of Pharmacology
Russian Federation, Saint PetersburgReferences
- Владимиров В.В., Меньшикова Л.В. Современные представления о псориазе и методы его лечения // РМЖ. - 1998. - Т. 6. - № 20. - С. 1318-1323. [Vladimirov VV, Men’shikova LV. Sovremennye predstavleniya o psoriaze i metody ego lecheniya. RMZh. 1998;6(20):1318-23. (In Russ.)]
- Короткий Н.Г., Уджуху В.Ю., Кубылинский А.А., Тихомиров А.А. Дайвобет - новый высокоэффективный препарат для наружного лечения больных среднетяжелым и тяжелым вульгарным псориазом // Клиническая дерматология и венерология. - 2007. - Т. 5. - № 4. - С. 64-69. [Korotkiy NG, Udzhukhu VY, Kubylinskiy АА, Tikhomirov АА. Dayvobet - novyy vysokoeffektivnyy preparat dlya naruzhnogo lecheniya bol’nykh srednetyazhelym i tyazhelym vul’garnym psoriazom. Klinicheskaia dermatologiia i venerologiia. 2007;5(4):64-69. (In Russ.)]
- Монахов К.Н., Хобейш М.М., Соколовский Е.В. Современные аспекты наружной терапии псориаза // Клиническая дерматология и венерология. - 2006. - Т. 4. - № 2. - С. 47-50. [Моnakhov КN, Khoybesh ММ, Sokolovskiy ЕV. Nowadays aspects of external therapy of psoriasis. Klinicheskaia dermatologiia i venerologiia. 2006;4(2):47-50. (In Russ.)]
- Некипелова A.B., Поляченко М.Н., Ислямова В.И. Опыт применения кальципотриола (псоркутана) в лечении псориаза // Вестник дерматологии и венерологии. - 1999. - № 5. - С. 46-47. [Nekipelova AV, Polyachenko МN, Islyamova VI. Opyt primeneniya kaltsypotrila (psorkutana) v lechenii psoriaza. Vestn Dermatol Venerol. 1999;(5):46-47. (In Russ.)]
- Петрова И.В., Омаров Н.Н., Саргсян М.С., и др. Поддерживающая фармакотерапия атопического дерматита // Обзоры по клинической фармакологии и лекарственной терапии. - 2018. - Т. 16. - № 1. - С. 60-63. [Petrova IV, Omarov NN, Sargsyan МS, et al. Maintenance pharmacotherapy of atopic dermatitis. Reviews on clinical pharmacology and drug therapy. 2018;16(1):60-63. (In Russ.)]. doi: 10.17816/RCF16160-63.
- Тогоева Л.Ш., Невозинская З.В., Корсунская И.М., и др. Наружная терапия ограниченных форм псориаза // Клиническая дерматология и венерология. - 2008. - Т. 6. - № 2. - С. 42-44. [Togoeva LS, Nevozinskaya ZV, Korsunskaya IМ, et al. External therapy of limited forms of psoriasis. Klinicheskaia dermatologiia i venerologiia. 2008;6(2):42-44. (In Russ.)]
- Филимонкова Н.Н., Кащеева Я.В., Чуверова К.А. Дерматотропные средства в комплексной терапии псориаза // Клиническая дерматология и венерология. - 2010. - Т. 8. - № 1. - С. 35-38. [Filimonkova NN, Каshcheeva YV, Chuverova КА. Dermatotropic agents for combined treatment of psoriasis. Klinicheskaia dermatologiia i venerologiia. 2010;8(1):35-38. (In Russ.)]
- Филимонкова Н.Н., Кащеева Я.В., Чуверова К.А. Клинический эффект последовательного назначения препаратов дайвобет и дайвонекс в комплексной терапии больных псориазом // Вестник дерматологии и венерологии. - 2006. - № 6. - С. 18-20. [Filimonkova NN, Каshcheeva YV, Chuverova КА. Clinical effect of consecutive application of daivobet and daivonex in combined therapy of psoriasis. Vestn Dermatol Venerol. 2006;(6):18-20. (In Russ.)]
- Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol. 1988;37(5):889-895. doi: 10.1016/0006-2952(88)90177-3.
- Choi CW, Kim BR, Park JS, Youn SW. Both Educational Lectures and Reference Photographs Are Necessary to Improve the Accuracy and Reliability of Psoriasis Area and Severity Index (PASI) Assessment: Results from Korean Nation-Wide PASI Educational Workshop. Ann Dermatol. 2018;30(3):284-289. doi: 10.5021/ad.2018.30.3.284.
- van Geel MJ, Mul K, Oostveen AM, et al. Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol. 2014;171(2):363-9. doi: 10.1111/bjd.12895.
- Kanelleas A, Liapi C, Katoulis A, et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 2011;36(8):845-850. doi: 10.1111/j.1365-2230.2011.04131.x.
- Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4):389-393. doi: 10.1159/000066440.
- Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150(6):1167-1173. doi: 10.1111/j.1365-2133.2004.05986.x.
- Saraceno R, Camplone G, D’Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol(R) gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30-3. doi: 10.3109/09546634.2013.800182.
- Shear NH, Hartmann M, Toledo-Bahena ME, et al. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice. Qual Life Res. 2016;25(8):2031-40. doi: 10.1007/s11136-015-1224-z.
- Tadros A, Vergou T, Stratigos AJ, et al. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? J Eur Acad Dermatol Venereol. 2011;25(11):1282-7. doi: 10.1111/j.1468-3083.2010.03965.x.
